Advancing Evidence-Based Value in Transthyretin Amyloidosis Cardiomyopathy Care: Managed Care Strategies for Early Identification, Access, and Treatment

Program Description:

Transthyretin amyloidosis (ATTR) is a progressive multisystem disorder characterized by misfolded protein accumulation. In ATTR cardiomyopathy (ATTR-CM), misfolded amyloid accumulation in the myocardium leads to severe heart failure, high cardiovascular morbidity, and significant mortality. Overlapping “red flag” symptoms such as carpal tunnel syndrome and heart failure with preserved ejection fraction frequently cause diagnostic delays, exacerbating functional decline and health care utilization. The treatment landscape ranges from TTR stabilizers to gene silencers and emerging gene-editing modalities, and selecting an optimal treatment requires balancing comparative efficacy, safety, route of administration, and phenotype-specific indications. Managed care pharmacists must navigate this rapidly evolving therapeutic landscape as these clinical nuances intersect with high drug costs and complex coverage models that require expertise with value-based contracting, early identification, and longitudinal tracking for optimal patient outcomes. This program will explore evolving clinical trial data and health economic considerations to help managed care professionals and pharmacists streamline diagnostic pathways, enhance multidisciplinary collaboration, and support equitable access to disease-modifying agents in ATTR-CM.

Target audience: Managed care pharmacists
Type of activity: Application
Release date: November 23, 2026
Expiration date: January 23, 2027
Time to complete activity: 1.0 hour
Learner level: Foundational, Intermediate
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Analyze the hallmark clinical features of transthyretin amyloidosis cardiomyopathy (ATTR-CM), including “red flag” symptoms, the complexity of differential diagnosis, and the clinical and economic impact of delayed care
• Compare the mechanistic targets, safety and efficacy profiles, and emerging and long-term clinical data associated with approved and late-stage investigational therapies for ATTR-CM to inform evidence-based utilization and treatment decision-making
• Factor the economic burden and cost of care associated with ATTR-CM into the development of value-based strategies that support evidence-based treatment and coordinated multidisciplinary care

Accreditation Information

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This application based activity is approved for 1.0 contact hour (0.10 CEU) under the ACPE universal activity number 0290-0000-26-336-L01-P. The activity is available for CE credit through January 23, 2027.

Obtaining Credit

All participants who attended the live virtual broadcast need to log on to their Pharmacy Times Continuing Education™ account on www.pharmacytimes.org to complete an online evaluation form and request their credit. Instructions on receiving credit will be provided the day of the event.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Disclosures

Victoria Wolf, PharmD, has no relevant financial relationships with ineligible companies to disclose.

Pharmacy Times Continuing Education™ Planning Staff: Jim Palatine, RPh, MBA; Dipti Desai, PharmD, MBA, CHCP; Sarah Viruet; and Brianna Winters have no financial relationships with ineligible companies to disclose.

All of the relevant financial relationships listed for these individuals have been mitigated.

At least 1 anonymous peer reviewer has been used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with ineligible companies to disclose.

Educational Disclaimer

CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms